Viking Therapeutics Inc
NASDAQ:VKTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.72
94.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Viking Therapeutics Inc
Viking Therapeutics Inc
Total Liabilities & Equity
Viking Therapeutics Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
Total Liabilities & Equity
$937.9m
|
CAGR 3-Years
61%
|
CAGR 5-Years
26%
|
CAGR 10-Years
85%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
|
Viking Therapeutics Inc
Glance View
Viking Therapeutics Inc. is an innovative biotechnology company dedicated to developing novel therapies for metabolic and endocrine disorders. With a strong focus on identifying and advancing unique drug candidates, Viking has carved a niche for itself in the competitive biopharmaceutical landscape. The company’s lead programs revolve around selective androgen receptor modulators (SARMs) and therapies aimed at improving insulin sensitivity and metabolism. By leveraging cutting-edge science and a team of experienced professionals, Viking aspires to offer transformative treatments for conditions such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), both of which present significant unmet medical needs in the healthcare market today. Investors are drawn to Viking Therapeutics not only for its promising drug pipeline but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company operates with a clear vision: to turn scientific innovation into viable treatments that improve patients' lives. As it advances its lead candidates through clinical trials and potentially toward the commercialization phase, Viking presents an intriguing opportunity for investors looking to engage with a company at the forefront of metabolic disease treatment. With a focus on best practices, rigorous clinical evaluation, and an eye on potential regulatory pathways, Viking Therapeutics is well-positioned to make a significant impact in the biotechnology field, all while offering the potential for substantial returns to its stakeholders.
See Also
What is Viking Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
937.9m
USD
Based on the financial report for Sep 30, 2024, Viking Therapeutics Inc's Total Liabilities & Equity amounts to 937.9m USD.
What is Viking Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
85%
Over the last year, the Total Liabilities & Equity growth was 145%. The average annual Total Liabilities & Equity growth rates for Viking Therapeutics Inc have been 61% over the past three years , 26% over the past five years , and 85% over the past ten years .
You don't have any saved screeners yet
